News
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Tuberculosis (TB) is a disease of mammoth proportions both in human lives lost and economic impact. Although preventative measures in this country have left the US relatively unscathed, TB is the second leading cause of death in adults worldwide. It disproportionately affects populations with poorer
Neglected diseases affect approximately 1 billion people, primarily in developing countries. However, since most R&D is not focused on neglected diseases, very few new treatments are brought to market. Through its partnerships with international public and private institutions, the NIH Office of
On March 15, 2006, the Meningitis Vaccine Project and the Serum Institute of India announced the successful completion of Phase I clinical trials of a new conjugate vaccine against meningitis A, a bacterium that causes deadly epidemics in sub-Saharan Africa. According to the Meningitis Vaccine